394 related articles for article (PubMed ID: 35381402)
1. Partial ligand shielding nanoparticles improve pancreatic ductal adenocarcinoma treatment via a multifunctional paradigm for tumor stroma reprogramming.
Zhao T; Zhang R; He Q; Zhou H; Song X; Gong T; Zhang Z
Acta Biomater; 2022 Jun; 145():122-134. PubMed ID: 35381402
[TBL] [Abstract][Full Text] [Related]
2. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer.
Li Y; Zhao Z; Lin CY; Liu Y; Staveley-OCarroll KF; Li G; Cheng K
Theranostics; 2021; 11(5):2182-2200. PubMed ID: 33500719
[No Abstract] [Full Text] [Related]
3. Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours.
Huang HC; Sung YC; Li CP; Wan D; Chao PH; Tseng YT; Liao BW; Cheng HT; Hsu FF; Huang CC; Chen YT; Liao YH; Hsieh HT; Shih YC; Liu IJ; Wu HC; Lu TT; Wang J; Chen Y
Gut; 2022 Sep; 71(9):1843-1855. PubMed ID: 34921062
[TBL] [Abstract][Full Text] [Related]
4. Sono-promoted drug penetration and extracellular matrix modulation potentiate sonodynamic therapy of pancreatic ductal adenocarcinoma.
Xiao H; Li X; Li B; Zhong Y; Qin J; Wang Y; Han S; Ren J; Shuai X
Acta Biomater; 2023 Apr; 161():265-274. PubMed ID: 36893956
[TBL] [Abstract][Full Text] [Related]
5. Stroma-targeting strategies in pancreatic cancer: a double-edged sword.
Liu X; Iovanna J; Santofimia-Castaño P
J Physiol Biochem; 2023 Feb; 79(1):213-222. PubMed ID: 36580230
[TBL] [Abstract][Full Text] [Related]
6. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition.
Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA;
Cancer Res; 2021 Jul; 81(13):3461-3479. PubMed ID: 33980655
[TBL] [Abstract][Full Text] [Related]
7. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
Liu H; Shi Y; Qian F
Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic cancer stroma: an update on therapeutic targeting strategies.
Hosein AN; Brekken RA; Maitra A
Nat Rev Gastroenterol Hepatol; 2020 Aug; 17(8):487-505. PubMed ID: 32393771
[TBL] [Abstract][Full Text] [Related]
9. Targeting cancer-associated fibroblasts by dual-responsive lipid-albumin nanoparticles to enhance drug perfusion for pancreatic tumor therapy.
Yu Q; Qiu Y; Li J; Tang X; Wang X; Cun X; Xu S; Liu Y; Li M; Zhang Z; He Q
J Control Release; 2020 May; 321():564-575. PubMed ID: 32112854
[TBL] [Abstract][Full Text] [Related]
10. Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment.
Luo Y; Li C; Zhang Y; Liu P; Chen H; Zhao Z; Wang Y; Zhou Z; Song H; Su B; Li C; Li X; Zhang T; You H; Wu Y; Tian Z; Zhang S; Guo Y; Fan H; Chen Q; Jiang C; Sun T
Acta Biomater; 2023 Sep; 167():387-400. PubMed ID: 37276955
[TBL] [Abstract][Full Text] [Related]
11. Sequential delivery of nanoformulated α-mangostin and triptolide overcomes permeation obstacles and improves therapeutic effects in pancreatic cancer.
Feng J; Xu M; Wang J; Zhou S; Liu Y; Liu S; Huang Y; Chen Y; Chen L; Song Q; Gong J; Lu H; Gao X; Chen J
Biomaterials; 2020 May; 241():119907. PubMed ID: 32120315
[TBL] [Abstract][Full Text] [Related]
12. Generation of an in vitro 3D PDAC stroma rich spheroid model.
Ware MJ; Keshishian V; Law JJ; Ho JC; Favela CA; Rees P; Smith B; Mohammad S; Hwang RF; Rajapakshe K; Coarfa C; Huang S; Edwards DP; Corr SJ; Godin B; Curley SA
Biomaterials; 2016 Nov; 108():129-42. PubMed ID: 27627810
[TBL] [Abstract][Full Text] [Related]
13. Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer.
Tsujii S; Serada S; Fujimoto M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Mol Cancer Ther; 2021 Dec; 20(12):2495-2505. PubMed ID: 34583978
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated fibroblasts reprogram cysteine metabolism to increase tumor resistance to ferroptosis in pancreatic cancer.
Zhu Y; Fang S; Fan B; Xu K; Xu L; Wang L; Zhu L; Chen C; Wu R; Ni J; Wang J
Theranostics; 2024; 14(4):1683-1700. PubMed ID: 38389839
[No Abstract] [Full Text] [Related]
15. Collagenase Nanoparticles Enhance the Penetration of Drugs into Pancreatic Tumors.
Zinger A; Koren L; Adir O; Poley M; Alyan M; Yaari Z; Noor N; Krinsky N; Simon A; Gibori H; Krayem M; Mumblat Y; Kasten S; Ofir S; Fridman E; Milman N; Lübtow MM; Liba L; Shklover J; Shainsky-Roitman J; Binenbaum Y; Hershkovitz D; Gil Z; Dvir T; Luxenhofer R; Satchi-Fainaro R; Schroeder A
ACS Nano; 2019 Oct; 13(10):11008-11021. PubMed ID: 31503443
[TBL] [Abstract][Full Text] [Related]
16. Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy.
He X; Chen X; Liu L; Zhang Y; Lu Y; Zhang Y; Chen Q; Ruan C; Guo Q; Li C; Sun T; Jiang C
Adv Sci (Weinh); 2018 May; 5(5):1701070. PubMed ID: 29876225
[TBL] [Abstract][Full Text] [Related]
17. Precise Photodynamic Therapy by Midkine Nanobody-Engineered Nanoparticles Remodels the Microenvironment of Pancreatic Ductal Adenocarcinoma and Potentiates the Immunotherapy.
Qu C; Yuan H; Tian M; Zhang X; Xia P; Shi G; Hou R; Li J; Jiang H; Yang Z; Chen T; Li Z; Wang J; Yuan Y
ACS Nano; 2024 Feb; 18(5):4019-4037. PubMed ID: 38253029
[TBL] [Abstract][Full Text] [Related]
18. Fibroblasts in pancreatic cancer: molecular and clinical perspectives.
Rebelo R; Xavier CPR; Giovannetti E; Vasconcelos MH
Trends Mol Med; 2023 Jun; 29(6):439-453. PubMed ID: 37100646
[TBL] [Abstract][Full Text] [Related]
19. Extracellular matrix modulating enzyme functionalized biomimetic Au nanoplatform-mediated enhanced tumor penetration and synergistic antitumor therapy for pancreatic cancer.
Yang XY; Zhang JG; Zhou QM; Yu JN; Lu YF; Wang XJ; Zhou JP; Ding XF; Du YZ; Yu RS
J Nanobiotechnology; 2022 Dec; 20(1):524. PubMed ID: 36496411
[TBL] [Abstract][Full Text] [Related]
20. NetrinG1
Raghavan KS; Francescone R; Franco-Barraza J; Gardiner JC; Vendramini-Costa DB; Luong T; Pourmandi N; Andren A; Kurimchak A; Ogier C; Campbell PM; Duncan JS; Lyssiotis CA; Languino LR; Cukierman E
Cancer Res Commun; 2022 Sep; 2(9):1017-1036. PubMed ID: 36310768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
